key: cord-0907829-us5ufqeg
authors: Lephart, Paul R.; Bachman, Michael; LeBar, William; McClellan, Scott; Barron, Karen; Schroeder, Lee; Newton, Duane W.
title: Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type
date: 2020-06-05
journal: bioRxiv
DOI: 10.1101/2020.06.04.135616
sha: 172bb478410dd4839db954a172670c63d60b6f33
doc_id: 907829
cord_uid: us5ufqeg

The advent of the COVID-19 pandemic in the United States created a unique situation where multiple molecular diagnostic assays with various indications for use in the detection of SARS-CoV-2 rapidly received Emergency Use Authorization by the FDA, were validated by laboratories and utilized clinically, all within a period of a few weeks. We compared the performance of four of these assays that were being evaluated for use at our institution: Abbott RealTime m2000 SARS-CoV-2 Assay, DiaSorin Simplexa COVID-19 Direct, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID NOW COVID-19. Nasopharyngeal and nasal specimens were collected from 88 ED and hospital-admitted patients and tested by the four methods in parallel to compare performance. ID NOW performance stood out as significantly worse than the other three assays despite demonstrating comparable analytic sensitivity. Further study determined that the use of a foam nasal swab compared to a nylon flocked nasopharyngeal swab, as well as use in a population chronically vs. acutely positive for SARS-CoV-2, were significant factors in the poor comparable performance.

The rapid onset of COVID-19 in the United States resulted in an accelerated pace of both 29 SARS-CoV-2 nucleic acid amplification test (NAAT) development and FDA Emergency Use 30 Authorization (EUA) approvals. Clinical microbiology laboratories that typically would take 31 weeks to evaluate and verify performance characteristics for a FDA approved diagnostic test had 32 little choice but to perform abbreviated validation and/or verification studies of assays, 33 benchmarked against limited FDA EUA performance data, in a matter of days. The sheer 34 volume of COVID-19 test requests from different patient populations, different specimen types, and with different turnaround time needs demanded that laboratories implement more than one 36 type of NAAT to respond to the crisis. 37 SARS-CoV-2 testing in our laboratory began with the CDC EUA assay performed on 38 Abbott m2000, but due to that assay's significant throughput constraints (24 specimens in 8 39 hours), we quickly verified and switched to the Abbott RealTime SARS-CoV-2 EUA Assay 40 (m2000) once released (94 specimens in ~8 hours). Although this assay provided capacity for 41 our outpatient testing needs, we also verified the DiaSorin Simplexa COVID-19 Direct 42 (Simplexa) assay, capable of resulting 8 specimens in 90 minutes, and used this assay as a rapid 43 turn-around time (TAT) option for our inpatient and emergency department (ED) populations.

Within a few weeks, additional SARS-CoV-2 NAAT options emerged that were specifically 45 designed for rapid testing of patients in the point of care setting: the Cepheid Xpert Xpress 46 SARS-CoV-2 (Xpert) assay, which could provide results in 45 minutes, and the Abbott ID NOW COVID-19 (ID NOW) assay, ultimately approved for direct nasal, nasopharyngeal and throat 48 swab testing only, with results in 5-15 minutes.

In the absence of clinical trials and a gold standard for COVID-19 diagnosis, the clinical 50 performance of SARS-CoV-2 assays is unclear. Anecdotal claims of poor NAAT performance 51 exist in the lay press, and limited studies have shown variable performance of rapid POC tests

(1-9). As a surrogate for a gold standard, a composite reference standard (CRS) can be used to 53 determine the consensus of comparable assays and identify outlier assays in terms of clinical 54 performance (10). Using this approach, our goal was to evaluate the performance-in parallel-55 of three NAATs from nasopharyngeal (NP) swabs in M4-RT viral transport medium (VTM) 56 (m2000, Xpert, Simplexa) and an NAAT assay performed directly from a nasal swab (ID NOW). TCID50/ml) that was internally quantified to 10 9.62 copies/mL relative to a standard curve of 84 AccuPlex™ SARS-CoV-2 Reference Material (SeraCare) constructed on the m2000 assay. From 85 that stock, dilutions were made in VTM (1,042, 521, 260, 130, 65 and 32.5 copies/mL) and 86 tested on the m2000, Simplexa, and Xpert SARS-CoV-2 assays. A separate set of ZeptoMetrix 87 dilutions in VTM were made so that when added to the 2.5 ml of elution buffer in the ID NOW 88 receiver cup, equivalent concentrations were achieved (1,042, 522, 262, 105 and 53 copies/mL).

In this way, the concentrations of viral copies in the ID NOW buffer were equivalent to the VTM 90 dilutions used for the other three instruments. Five replicates at each dilution were tested.

Nasal swabs directly tested on the ID NOW assay had 48% positive agreement compared 94 to the CRS, whereas Simplexa had 88%, m2000 had 96% and Xpert had 100% positive 95 agreement (Table 1) . While the deficit in positive percent agreement (PPA) seen in ID NOW 96 test results is consistent with other early release studies in the scientific literature ((1-4, 7-9) ), it 97 is surprising given the ID NOW's LOD claim of 125 genome equivalents/mL, which is similar to 98 the 100 copies/mL claimed by the m2000 method, 250 copies/mL claimed by Xpress and 242 99 copies/mL claimed by Simplexa. To clarify this apparent discrepancy, a direct assessment of the 100 analytic sensitivity of all assays in this comparison was performed utilizing dilutions of 101 inactivated SARS-CoV-2 whole virus (ZeptoMetrix). In this limited LOD study, we found each assay had comparable LODs to the reported LOD data in their package insert, including the LOD 103 of the ID NOW assay, as shown in Table 2 . 104 Similarities in the LODs among the assays suggest that other factors contribute to the 105 differences in comparative performance when testing clinical specimens. When additional ID 106 NOW testing was performed on the 25 NP VTM specimens that were positive based on the CRS, 107 6 additional patients were detected that were negative by nasal swab testing. This suggests that 108 testing an NP swab in VTM on ID Now may have better performance than a direct nasal swab, 109 as use of the NP VTM improves the PPA from 48% to 64%. However, testing an NP swab in 110 VTM was recently removed as an approved source from the original ID NOW package insert 111 based on concerns about false negatives, whereas a nasal swab is provided as an approved 112 collection device. The sensitivity issues leading up to that removal may have less been due to 113 VTM than the quality of a nasal specimen itself when compared to a NP specimen. Further 114 studies should be conducted directly comparing the performance of direct (not placed in VTM)

NP swabs on the ID NOW to NP swabs in VTM tested by other NAATs.

An important variable in our study is that two distinct population groups were analyzed. Ct values as measured by Abbott m2000 Ct (n=9, mean Ct 21.6) than positive specimens 124 collected from patients presenting at the ED (n=16, mean Ct 16.3, p-value 0.04). As the majority of ID NOW negative/m2000 positive specimens (8 of 12) were from this inpatient population of 126 low Ct positives, the overall performance of the ID NOW assay was substantially impacted. To 127 assess test performance in a more typical use case in a POC setting, we reanalyzed percent 128 agreement for all assays using only ED patients. While still notably lower than the other assays, 129 the PPA of ID NOW increased from 48 to 69%, whereas performance of the other assays was 130 nearly identical (Table 1b) .

This comparative analysis of SARS-CoV-2 NAATs utilizing the m2000, Simplexa, Xpert 132 and ID NOW assays demonstrated that significant performance deficits were found in the ID 133 NOW assay when tested in a mixed patient population using both NP and nasal specimens.

Based on a CRS, use of the m2000, Xpert, and Simplexa assays for NP specimens in VTM are 

Comparison 164 of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from 165 nasopharyngeal and nasal swabs from symptomatic patients

Evaluation of the COVID19 ID NOW EUA assay

Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 171 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19

Comparison of Cepheid Xpert Xpress 174 and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2

Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the first rapid multiplex PCR 179 commercial assay for SARS-CoV-2 detection

Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during 183 the SARS-CoV-2 pandemic

Answer Platforms for the Detection of SARS-CoV-2

Wongchaowart 187 N, Fuhrman S, Antonara S. 2020. Clinical Evaluation and Utilization of Multiple Molecular In Vitro 188

Diagnostic Assays for the Detection of SARS-CoV-2

Comparison of two commercial 190 molecular tests and a laboratory-developed modification of the CDC 2019-nCoV RT-PCR assay 191 for the detection of SARS-CoV-2

Diagnostic 193 Performance of Chest X-Ray for COVID-19 Pneumonia During the SARS-CoV-2 Pandemic

P value P value summary 0.0005 ***